en
Pharmaceuticals
Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
A C D E F G I L M N P R S T V X Z
Aclasta*
(zoledronic acid injection)
Bone Metabolism Regulator
Important information for healthcare professionals (2010)
Important information for healthcare professionals (2005)
*Aclasta is a registered trademark
Afinitor*
(everolimus tablets)
mTOR Kinase Inhibitor
*Afinitor is a registered trademark
Aredia*
(pamidronate disodium for injection)
Bone Metabolism Regulator
Important information for healthcare professionals (2004)
*Aredia is a registered trademark
Research
Novartis is one of the industry’s biggest investors in research.
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.